Skip to main content

Ovarian Cancer

Featured Article
A US cost comparison of PARP inhibitors used to treat women with ovarian cancer found one in particular to have the lowest monthly cost for payers.
Work loss costs associated with absenteeism, short-term disability, and long-term disability were two-to-four times higher for patients with ovarian cancer who took leave after initiating…

Insights

Sarah M Temkin, MD, and Don Dizon, MD, discuss the benefits of PARP inhibitors for treating ovarian cancer and why effectiveness, toxicity, safety, and cost must be balanced for an individual patient to determine the right PARP inhibitor for the…
Patients diagnosed with neuroendocrine tumors often experience different burdens associated with the disease resulting in costly treatments of thousands of dollars per year.

Interactive Features

Sarah Temkin, MD, board-certified gynecologic oncologist, and Don Dizon, MD, oncologist specializing in women’s cancers, discuss an ongoing Phase III trial that examines the use of selinexor for the treatment of endometrial cancer, and highlight…
Many elderly cancer patients take complementary or alternative medicines, which can make anticancer therapies less effective or cause dangerous drug-drug and drug-disease interactions. Do you know which is their favorite?
One household pet could hold the key to improving the delivery of targeted therapies in bone cancer patients.
Who is most likely to suffer the side effects associated with sorafenib therapy? Patients with advanced thyroid cancer, renal cell carcinoma, or hepatocellular carcinoma?
Back to Top